A physician practice that bills a molecular diagnostic or genomic test answers to more than one Medicare rulebook. Most of these claims run through MolDX, the molecular diagnostics program Palmetto GBA built and that CGS and Noridian now administer in their own jurisdictions. MolDX conditions payment on a DEX Z-Code identifier assigned to the specific test and, for many tests, a completed Technical Assessment. A claim that skips either step risks a denial, and a pattern of denials can draw the same post-payment review tools already used across Medicare audit defense.
What the MolDX Program Actually Reviews
MolDX is a coverage, coding, and payment program that Medicare Administrative Contractors run under their own local coverage determinations, not CMS staff reviewing every claim by hand. Palmetto GBA created MolDX in 2011; other MACs adopt its technical determinations in their own jurisdictions. Under local coverage determination L36021, CGS Administrators has accepted Palmetto GBA's MolDX determinations for its Kentucky and Ohio jurisdiction since September 16, 2013, and Noridian runs the same Z-Code and Technical Assessment requirements in its own jurisdictions. MolDX is a review function several contractors each operate locally, not one national office.
DEX Z-Codes and the Technical Assessment
A laboratory that wants Medicare to pay for a molecular test first registers it with the DEX Diagnostics Exchange, receives a Z-Code identifier specific to that assay, and submits it with the claim for reimbursement. Many tests also need a Technical Assessment first: the lab submits a dossier showing the test's analytical validity, clinical validity, and clinical utility at a level that meets Medicare's reasonable and necessary standard. Not every test needs this step. An FDA-approved or FDA-cleared test billed consistent with its own labeling does not require a Z-Code with the appropriate ICD-10 code. A test billed under an unlisted code such as CPT 87999, multiple same-day tests for the same clinical use, or an off-label use of an otherwise FDA-cleared assay, each still requires its own Z-Code and Technical Assessment.
A molecular test billed under the correct CPT code can still go unpaid if the claim is missing its DEX Z-Code, the one identifier Medicare's own system is built to check.
How a Claim Gets Reviewed for Its Z-Code
The Z-Code goes directly on the claim, in the comment or narrative field next to the CPT code, such as Box 19 on a paper claim, rather than on a separate form. The Medicare Administrative Contractor that issued the test's local coverage determination checks for that field before paying the claim, not CMS staff directly. The performing laboratory usually submits the Z-Code, but the ordering physician's documentation still has to support medical necessity, because that record is what a reviewer pulls first if the claim is flagged for post-payment review.
Coverage Limits That Catch Physician Offices
MolDX local coverage determinations also cap how often a test can be billed. A genomic profile (CGP) test is limited to one test per surgical specimen. Minimal residual disease testing for solid tumor cancers allows one test per cancer diagnosis, absent evidence the tumor's genetic content changed, and no more than monthly testing for patients without cancer. A molecular syndromic panel generally cannot repeat for the same clinical indication, except for one additional panel between one and 14 days after the first. Billing outside those limits, or without the right Z-Code, can draw a RAC review or a Medicare Administrative Contractor post-payment audit. Once enough claims are flagged, the contractor can apply extrapolation across the practice's full lookback period rather than the sampled claims alone, turning a handful of molecular diagnostic claims into a six- or seven-figure recoupment demand.
Physicians who order these tests face the same audit tools used elsewhere in Medicare review. A Medicare additional documentation request can ask for the Z-Code and Technical Assessment records directly, and a practice that catches its own billing error first is often better served by self-disclosing a Medicare overpayment than by waiting for a recoupment letter. The same documentation gap already shows up in Medicare's review of remote patient monitoring claims.
Why Early Legal Counsel Is Critical
It is critical that physician practices and laboratories promptly retain experienced healthcare defense counsel once a MolDX claim is denied, a Technical Assessment is questioned, or a Medicare Administrative Contractor opens a post-payment review. Early legal intervention can protect the practice's rights, help shape the response to a documentation request, avoid inadvertent admissions, and preserve defenses before a sampled review becomes an extrapolated demand. Waiting until the recoupment letter arrives can affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Health Law Alliance's Medicare audit defense attorneys review MolDX denials, Technical Assessment disputes, and post-payment documentation requests for physician practices and laboratories billing molecular diagnostic tests. If a Medicare Administrative Contractor has flagged a molecular or genetic testing claim, contact us for a free, confidential consultation before the matter becomes a recoupment demand.





